News
RDHL
0.8229
+1.59%
0.0129
RedHill Biopharma Receives Nasdaq Minimum Bid Price Deficiency Notice
TipRanks · 1d ago
Weekly Report: what happened at RDHL last week (0406-0410)?
Weekly Report · 2d ago
Weekly Report: what happened at RDHL last week (0330-0403)?
Weekly Report · 04/06 10:10
Weekly Report: what happened at RDHL last week (0323-0327)?
Weekly Report · 03/30 10:10
Weekly Report: what happened at RDHL last week (0316-0320)?
Weekly Report · 03/23 10:06
Weekly Report: what happened at RDHL last week (0309-0313)?
Weekly Report · 03/16 10:06
Weekly Report: what happened at RDHL last week (0302-0306)?
Weekly Report · 03/09 10:06
RedHill Biopharma Shareholders Approve RSU Grants and Share Capital Increase
TipRanks · 03/05 14:32
Cumberland Pharmaceuticals 2025 revenue rises
Reuters · 03/03 22:12
Weekly Report: what happened at RDHL last week (0223-0227)?
Weekly Report · 03/02 10:06
RedHill Biopharma announces full sales and operational launch of Talicia
TipRanks · 02/25 12:17
RedHill Biopharma Says Full Sales And Operational Launch Of Talicia, Under Joint Commercialization Agreement Between Talicia And Cumberland Pharmaceuticals Has started
Benzinga · 02/25 12:11
Cumberland Pharmaceuticals and RedHill Biopharma Co-Commercialize Talicia in U.S
Reuters · 02/25 12:01
Weekly Report: what happened at RDHL last week (0216-0220)?
Weekly Report · 02/23 10:06
Weekly Report: what happened at RDHL last week (0209-0213)?
Weekly Report · 02/16 10:06
Weekly Report: what happened at RDHL last week (0202-0206)?
Weekly Report · 02/09 10:07
Weekly Report: what happened at RDHL last week (0126-0130)?
Weekly Report · 02/02 10:07
RedHill Biopharma Calls March 5 Extraordinary Meeting to Approve RSU Grants and Share Capital Increase
TipRanks · 01/27 12:27
Weekly Report: what happened at RDHL last week (0119-0123)?
Weekly Report · 01/26 10:06
RedHill Biopharma Calls March 5, 2026 Extraordinary Meeting to Approve RSU Grants and Share Capital Increase
TipRanks · 01/22 14:17
More
Webull provides a variety of real-time RDHL stock news. You can receive the latest news about Redhill Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About RDHL
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.